hassan noorbazargan | Immunology | Best Researcher Award

Published on by Academic Excellence

Dr. hassan noorbazargan | Immunology | Best Researcher Award

Dr. hassan noorbazargan | Immunology | Carbon Technologies LLC | Oman 

Dr. Hassan Noorbazargan is a highly accomplished researcher specializing in biotechnology, immunology, and molecular diagnostics. He earned his Ph.D. in Medical Biotechnology from Shahid Beheshti University of Medical Sciences, Iran, where his doctoral work focused on the design and validation of advanced PCR assays for detecting HIV. His career reflects a strong combination of academic excellence and industrial expertise, spanning molecular diagnostics, vaccine production, recombinant protein development, and nanobiotechnology. Dr. Noorbazargan has held prominent roles at Carbon Technologies Co., ROJE Technologies, and the Pasteur Institute of Iran, where he contributed significantly to diagnostic assay development and vaccine quality control. His research contributions have led to impactful publications on nanocarriers, drug delivery, and novel therapeutic strategies for infectious diseases and cancer. Dedicated to advancing biotechnology and immunology, Dr. Noorbazargan continues to shape the scientific community with his innovative work, quality leadership, and pursuit of translational research.

Author Profiles

Orcid | Google Scholar

Education 

Dr. Hassan Noorbazargan pursued his Ph.D. in Biotechnology at Shahid Beheshti University of Medical Sciences, where he achieved a perfect GPA. His doctoral thesis focused on the design, development, and application of TaqMan real-time PCR for qualitative and quantitative detection of HIV, demonstrating his expertise in molecular diagnostics. Prior to this, he earned his M.Sc. in Microbiology from Islamic Azad University of Lahijan, where his thesis involved cloning and expression of the HCV core+1 protein in mammalian cells, highlighting his interest in virology and genetic engineering. He also completed his B.Sc. in Microbiology from the same university, where he developed a strong foundation in immunology, biochemistry, and cell biology. Through his academic journey, he undertook multiple research assistantships in microbiology and biotechnology labs, which helped refine his practical laboratory expertise. His educational achievements underline a consistent pursuit of excellence and research-driven learning.

Experience

Dr. Hassan Noorbazargan brings extensive experience in both academia and industry, specializing in diagnostics, vaccines, and nanobiotechnology. Currently serving as Senior Researcher & QC Head at Carbon Technologies Co., Muscat (2024–Present), he leads diagnostic kit validation for infectious diseases and ensures regulatory compliance. From 2019–2024, as Head of R&D at ROJE Technologies, he developed PCR assays for HIV, Hepatitis, and Influenza while managing technology transfer and GMP compliance. Earlier, he was a Senior R&D Specialist at Sinaclon, focusing on scaling molecular reagents and diagnostic kits. At the Pasteur Institute of Iran, he contributed as a Senior Scientist in BCG vaccine production and later as Scientific Advisor in vaccine development. His career also includes supervisory roles in clinical diagnostics and hands-on experience as a hospital lab technician. With a proven record in assay development, recombinant proteins, and nanocarriers, Dr. Noorbazargan continues to bridge research with translational healthcare solutions.

Awards and Honors

Throughout his career, Dr. Hassan Noorbazargan has earned recognition for his academic and research excellence in biotechnology and immunology. He successfully completed his Ph.D. with distinction at Shahid Beheshti University of Medical Sciences, where his groundbreaking work on HIV molecular detection positioned him as a leading scholar in molecular diagnostics. His innovative publications on nanocarriers, drug delivery systems, and novel therapeutic strategies for cancer and infectious diseases have been widely cited, reflecting their significant impact on the scientific community. He has also been acknowledged for his leadership in R&D roles, particularly in vaccine development and molecular assay validation, where his contributions directly influenced product innovation and clinical applications. In addition, Dr. Noorbazargan has participated in global training programs offered by WHO Academy, IAVI, Coursera, and edX, further strengthening his expertise. His ongoing pursuit of excellence and translational research has earned him recognition as a promising researcher in biotechnology and immunology.

Research Focus

Dr. Hassan Noorbazargan’s research is deeply rooted in immunology, nanobiotechnology, and molecular diagnostics. His focus lies in developing advanced diagnostic assays, nanocarrier-based drug delivery systems, and recombinant proteins for therapeutic and preventive medicine. A significant part of his work addresses infectious diseases such as HIV, Hepatitis, and COVID-19, where he has designed and validated cutting-edge PCR and ELISA-based assays for accurate detection. Beyond infectious diseases, his research explores innovative cancer therapies using niosomes, nanogels, and metal-organic frameworks for targeted and site-specific drug delivery. His publications highlight enhanced antibacterial, anticancer, and anti-metastatic strategies through engineered nanostructures, offering breakthroughs in precision medicine. He also contributes to vaccine research, optimizing immunogenicity assays and quality systems to improve vaccine safety and efficacy. By integrating molecular biology, immunology, and biotechnology, Dr. Noorbazargan’s research strengthens the bridge between laboratory innovation and clinical application, ultimately advancing global healthcare outcomes.

Publications

  • Narrative review on traditional medicine options for COVID-19 treatment.

  • Curcumin-loaded niosome nanocarriers for breast cancer therapy.

  • Ciprofloxacin-encapsulated niosomes for enhanced antibacterial activity.

  • Doxycycline-loaded niosomal formulation for prostate cancer treatment.

  • Niosome-loaded selenium nanoparticles for antibacterial and anticancer activities.

  • Folate-conjugated nanogels encapsulating oxaliplatin for colorectal cancer therapy.

  • Silver nanoparticles from Juniperus chinensis with anticancer properties.

  • Cefazolin-encapsulated UIO-66-NH2 nanoparticles against resistant S. aureus.

  • Folate-targeted curcumin-loaded niosomes for breast cancer treatment.

  • Biogenic AgNPs from Artemisia oliveriana for lung cancer therapy.

  • Engineered UIO-66 MOF delivering curcumin for breast cancer cells.

  • Super magnetic niosomal nanocarriers for breast cancer therapy.

Conclusion

Dr. Hassan Noorbazargan is a promising scientist whose research combines immunology, molecular diagnostics, and nanomedicine to address critical challenges in infectious diseases and cancer. With a balance of academic achievements, industrial expertise, and impactful publications, he stands as a strong candidate for global recognition in biomedical research.

 

Kiran Kharsodiya | Immunology | Women Researcher Award

Published on by Academic Excellence

Dr. Kiran Kharsodiya | Immunology | Women Researcher Award

Dr. Kiran Kharsodiya | Immunology | Mody University of Science and Technology | India

Kiran Kharsodiya is a dedicated Research Scientist and Microbiologist with over eight years of experience in clinical, pharmaceutical, and microbiological research. Currently serving as Project Research Scientist II under the ICMR-CAR-MEDTECH Project at St. John’s Research Institute, Bengaluru, Kiran has made impactful contributions in designing and executing large-scale intervention and medical device trials. His expertise lies in microbiological examination, molecular analysis, and the study of host-inflammatory pathways. Kiran holds a strong research background supported by multiple peer-reviewed publications in international journals, reflecting his commitment to advancing medical science. His doctoral research at Mody University focuses on microbiological and molecular analysis of abnormal vaginal discharge and its pathophysiological effects, bridging microbiology and women’s health. A recipient of CSIR-NET qualification in 2024, Kiran exemplifies innovation, critical thinking, and leadership in translational research. His collaborative approach and scientific rigor continue to shape impactful research outcomes with real-world clinical applications.

Author Profiles

Orcid | Google Scholar

Education

Kiran Kharsodiya has pursued a strong academic foundation in microbiology and life sciences, which has shaped his career in biomedical research. He is currently completing his Doctor of Philosophy (PhD) at Mody University, India, where his thesis focuses on “Microbiological Examination and Molecular Analysis in Abnormal Vaginal Discharge and Comparative Analysis of its Pathophysiological Effect.” His PhD integrates molecular biology with clinical microbiology to explore diagnostic and therapeutic strategies in women’s health. Kiran earned his Master of Science (Microbiology) degree from Devi Ahilya University, Indore, India, where he specialized in advanced microbiological techniques and clinical research applications. He also completed a Bachelor of Science (Industrial Microbiology) from the same university, where his academic excellence and research curiosity laid the foundation for his career. Complementing his education, he successfully qualified the prestigious CSIR-NET exam in 2024, showcasing his academic excellence and research potential.

Experience

Currently working as Project Research Scientist II at St. John’s Research Institute, Bengaluru, under the ICMR-CAR-MEDTECH Project (2024–present), Kiran Kharsodiya brings extensive expertise in microbiology and clinical trial management. His role involves designing and executing large-scale pharmaceutical, medical device, and clinical trials, with a focus on ensuring regulatory compliance and high-quality data collection. He actively contributes to Phase III trials, large intervention efficiency studies, and the development of non-medical trial protocols. His ability to coordinate daily operations, collaborate with multidisciplinary teams, and analyze clinical trial data demonstrates his strong leadership in research environments. Kiran is also skilled in publishing and disseminating research findings through scientific journals and conferences, reinforcing his contributions to the broader scientific community. With more than eight years of research experience, he has developed a reputation for innovation, scientific precision, and problem-solving, contributing significantly to advancing biomedical and microbiological research in India and beyond.

Awards and Honors

Throughout his career, Kiran Kharsodiya has consistently demonstrated academic excellence and research dedication, earning several notable distinctions. His most recent achievement includes qualifying the prestigious CSIR-NET examination in 2024, a highly competitive recognition that reflects his advanced scientific knowledge and potential for research leadership. His contributions to translational microbiological and clinical research have also been acknowledged through multiple peer-reviewed publications, a testament to his innovation and dedication. Kiran has been invited to present his findings at national and international scientific conferences, highlighting the global relevance of his work. His collaborative research within multi-institutional projects, such as the ECGRI study on endometriosis and ovarian cancer, further underscores his recognition within the scientific community. These milestones, combined with his proven ability to integrate microbiology, molecular biology, and clinical research, establish him as a promising scientist whose work continues to be recognized for both academic rigor and societal impact.

Research Focus

Kiran Kharsodiya’s research focus lies at the intersection of microbiology, immunology, and women’s health. His PhD work emphasizes microbiological examination and molecular analysis of abnormal vaginal discharge, aiming to identify pathogenic flora, host-inflammatory responses, and their pathophysiological effects. This contributes to better diagnostic and therapeutic strategies for gynecological conditions. His studies also expand into the role of biomarkers, such as cytokines and microRNAs, in diseases like endometriosis and ovarian cancer, highlighting his interest in translational research. By integrating clinical microbiology, immunological pathways, and molecular diagnostics, Kiran seeks to improve early detection and intervention in reproductive health disorders. His work extends to exploring host-pathogen interactions, inflammation markers such as IL-6, IL-1β, TNF-α, and their predictive value in microbial infections. This research bridges fundamental microbiology with clinical applications, addressing pressing healthcare challenges. His long-term goal is to advance diagnostic tools and contribute meaningfully to global women’s healthcare solutions.

Publications

  • Protocol for a case–control study investigating the clinical phenotypes and genetic regulation of endometriosis in Indian women: the ECGRI study.

  • The relationship between melatonin 1-2 receptor expression in patients with epithelial ovarian cancer and survival.

  • Endometriosis in India: Analysing diagnostic delays, geographic variations, clinical phenotypes and associated characteristics from the ECGRI Study.

  • Predictive value of IL-6, IL-1β, TNF-α, and vaginal pH in diagnosing vaginal microbial infections: A host-inflammatory axis perspective.

  • Identification and characterization of pathogenic microbial flora associated with abnormal vaginal discharge: A microbiological examination study.

  • A pilot study of circulating microRNA-125b as a diagnostic & prognostic biomarker for epithelial ovarian cancer.

  • 2022-RA-195-ESGO miRNA-125b expression in epithelial ovarian cancer.

Conclusion

Kiran Kharsodiya is a dynamic researcher with strong expertise in microbiology, immunology, and clinical research, making significant contributions to women’s health and translational medicine. His blend of academic rigor, practical experience in large-scale trials, and impactful publications positions him as a promising leader in biomedical sciences. With a clear focus on innovation, collaboration, and clinical relevance, he continues to advance knowledge at the crossroads of microbiology and immunology, striving to improve diagnostic and therapeutic outcomes for global healthcare.

Ricardo Dario Zwiener | Allergy | Academic Excellence Award

Published on by Academic Excellence

Dr. Ricardo Dario Zwiener | Allergy | Academic Excellence Award

Dr. Ricardo Dario Zwiener, Instituto de inmunoalergia Dr. Zwiener, Argentina

Dr. Ricardo Dario Zwiener is a distinguished physician with over 20 years of experience specializing in Internal Medicine and Clinical Allergology and Immunology. He currently serves as the Medical Director and Head of Research & Education at the Centro de Alergia e Inmunología Dr. Zwiener, as well as a Clinical Allergy and Immunology Department leader at Hospital Universitario Austral. Dr. Zwiener has a passion for research, particularly in Hereditary Angioedema, Severe Asthma, and other allergic conditions. His approach blends evidence-based medicine with a deep commitment to patient care, fostering a collaborative and open dialogue with his patients. As a speaker, educator, and author, he has contributed to numerous publications, becoming a trusted voice in the global allergy and immunology community.

Professional Profile

Scopus

Orcid

Suitability For the Academic Excellence Award

Dr. Ricardo Dario Zwiener is an exemplary candidate for the Research for Academic Excellence Award, given his extensive and impactful contributions to the fields of Internal Medicine, Clinical Allergy, and Immunology. Over the span of his two-decade career, Dr. Zwiener has held pivotal roles in medical leadership, particularly as the Medical Director and Head of Research & Education at the Centro de Alergia e Inmunología Dr. Zwiener. His clinical expertise is reflected in his work at the Hospital Universitario Austral, where he has made significant strides in advancing knowledge on hereditary angioedema, severe asthma, and other immunological disorders.

Dr. Zwiener’s involvement in groundbreaking clinical research, such as his studies on hereditary angioedema (HAE) and severe asthma, underscores his commitment to improving patient outcomes through innovative therapeutic approaches. His participation in high-profile studies, including the Geo Study (Takeda) and the Reveal Study (Sanofi), demonstrates his dedication to evidence-based medicine. His publication record is equally impressive, with contributions to notable journals such as the Journal of Allergy and Clinical Immunology, where he has co-authored pivotal research on chemotherapy-induced anaphylaxis and allergic rhinitis treatment.

🎓 Education

Dr. Zwiener earned his medical degree from the University of Buenos Aires and has pursued advanced specialization in Internal Medicine and Clinical Allergology. His dedication to furthering his medical knowledge is evident in his extensive post-graduate studies and certifications in allergy and immunology. Throughout his career, Dr. Zwiener has been involved in several educational initiatives, both locally and internationally, providing insight into his areas of expertise. He continues to engage in educational programs to ensure that he stays at the forefront of new developments in his field, ensuring that his practice is grounded in the latest medical advances.

💼 Professional Experience

Dr. Ricardo Dario Zwiener has an extensive career spanning two decades in the medical field. He began his journey at Hospital Universitario Austral, where he specialized in Internal Medicine and later transitioned to the Allergy and Immunology Department. Since 2007, he has served as a key member of the Clinical Allergy and Immunology Department at the same hospital. In 2018, Dr. Zwiener founded and became the Medical Director of Centro de Alergia e Inmunología Dr. Zwiener, where he focuses on innovative research and education. His expertise in managing complex allergic conditions, especially hereditary angioedema, has led him to collaborate on various high-profile studies and clinical trials, driving advancements in allergy treatments and patient care.

🏅 Awards and Recognition

Dr. Zwiener has been recognized internationally for his contributions to allergy and immunology. His work in hereditary angioedema and severe asthma has been acknowledged through numerous awards, including the Best Oral Presentation at the 11th C1-Inhibitor Deficiency & Angioedema Workshop in Budapest in 2019. In addition, his research has been cited in renowned journals such as Allergy, Journal of Allergy and Clinical Immunology, and Rev Alerg Mex. His dedication to advancing the field has earned him prestigious distinctions, including recognition for his involvement in the GA2 LEN/HAEi Angioedema Centers of Reference and Excellence project.

🌍 Research Skills On Allergy

Dr. Zwiener’s research is primarily focused on hereditary angioedema, severe asthma, and the immunological aspects of allergic diseases. He has spearheaded multiple clinical trials, including the Geo study for hereditary angioedema and the Reveal Study for severe asthma, aiming to improve diagnosis, treatment, and patient outcomes. His research efforts extend to assessing the incidence and risk factors for chemotherapy-induced anaphylaxis, contributing valuable insights to the allergy and immunology community. His skills in conducting innovative clinical studies, as well as his ability to translate research into practical applications, have solidified his reputation as a leader in the field.

📖 Publication Top Notes

  • Assessing the accuracy of ChatGPT’s responses to common allergy myths
    • Authors: Estrada-Mendizabal, R.J., Cojuc-Konigsberg, G., Labib, E.N., … , Zwiener, R., Canel-Paredes, A.
    • Citation: Journal of Allergy and Clinical Immunology: In Practice, 2024.
    • Citations: 0
  • A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative
    • Authors: Zuberbier, T., Abdul Latiff, A., Aggelidis, X., … , Zwiener, R., Worm, M.
    • Citation: Clinical and Translational Allergy, 2023, 13(9), e12299.
    • Citations: 2
  • COVID-19 triggers attacks in HAE patients without worsening disease outcome
    • Authors: Olivares, M.M., Zwiener, R.D., Panqueva, L.M.L., … , Leyva Barrero, R.R., Grumach, A.S.
    • Citation: Journal of Allergy and Clinical Immunology: In Practice, 2022, 10(3), pp. 855–858.
    • Citations: 8
  • Chemotherapy-induced anaphylaxis and fatal anaphylaxis in the United States: Incidence and risk factors
    • Authors: Bojanini, L., Morgenstern-Kaplan, D., Carrillo-Martin, I., … , Zwiener, R., Gonzalez-Estrada, A.
    • Citation: Clinical and Experimental Allergy, 2021, 51(11), pp. 1514–1518.
    • Citations: 2
  • Treatment of allergic rhinitis in adults in Argentina. Update document
    • Authors: Vazquez, D., Onetti, C.I., Moreno, P., … , Ardusso, L., Fantini, C.
    • Citation: Archivos de Alergia e Inmunologia Clinica, 2021, 52(Supplement 001), pp. 7–36.
    • Citations: 0
  • Consensus on the diagnosis and treatment of hereditary angioedema (HAE) in Argentina
    • Authors: Vazquez, D.O., Josviack, D.O., Fantini, C.A., … , Strass, M.D., Fabiani, J.E.
    • Citation: Archivos de Alergia e Inmunologia Clinica, 2021, 52(Supplement 002), pp. 6–13.
    • Citations: 1
  • Argentine consensus of the diagnosis and treatment of hereditary angioedema
    • Authors: Vazquez, D.O., Josviack, D.O., Fantini, C.A., … , Strass, M.D., Fabiani, J.E.
    • Citation: Revista Alergia Mexico, 2021, 68(6), pp. S1–S22.
    • Citations: 4
  • Severe cutaneous adverse reactions to drugs in Latin America: The RACGRAD study
    • Authors: Rojas Mejía, D.V., Zwiener, R.D., Cardona Villa, R., … , Jares, E., Serrano Reyes, C.D.
    • Citation: Journal of Investigational Allergology and Clinical Immunology, 2021, 31(4), pp. 322–331.
    • Citations: 6
  • Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence
    • Authors: Maurer, M., Aberer, W., Agondi, R., … , Zwiener, R.D., Castaldo, A.
    • Citation: Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75(8), ALL14293.
    • Citations: 36
  • Immunology of Bee Venom
    • Authors: Elieh Ali Komi, D., Shafaghat, F., Zwiener, R.D.
    • Citation: Clinical Reviews in Allergy and Immunology, 2018, 54(3), pp. 386–396.
    • Citations: 71